Actively Recruiting
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Led by Guangzhou Jiayin Biotech Ltd · Updated on 2025-08-15
42
Participants Needed
1
Research Sites
298 weeks
Total Duration
On this page
Sponsors
G
Guangzhou Jiayin Biotech Ltd
Lead Sponsor
P
Peking University People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
CONDITIONS
Official Title
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Previously received treatment with EXG102-031 in the study (EXG102-031-111)
- Participants provide informed consent and are willing to follow study procedures
You will not qualify if you...
- Participants unwilling or unable to participate in long-term follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, China
Actively Recruiting
Research Team
S
Sara Yang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here